FDA Urges Doctors to Weigh Risks when Prescribing Depakote to Women According to CJF

FDA Urges Doctors to Weigh Risks when Prescribing Depakote to Women According to CJF New information about Depakote pregnancy risks has led the FDA to urge healthcare professionals to carefully weigh all benefits and risks of Depakote treatment before prescribing the drug to women of childbearing age. Depakote is one of the most commonly prescribed anticonvulsant medications, used in the treatment of epilepsy, seizures, migraine headaches and bipolar disorder. For more information about potential Depakote birth defects or to contact a Depakote attorney, visit http://www.DepakoteBirthInjury.
Contributor
PR Web
PR Web
Lanham, Maryland
Law Marketing
1.800.345.5572
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Download

Related Documents in PR Web
MCLE Sales

Categories